Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Revolutionary Autoinjector Pushes the Limits of High Viscosity Drug Delivery

Published: Thursday, April 18, 2013
Last Updated: Thursday, April 18, 2013
Bookmark and Share
Successful delivery of 1100 cPs solutions through a 25G thin wall needle in less than 7 seconds.

Oval Medical Technologies Ltd (‘Oval’) has announced that a variety of 1100 cPs solutions (the thickness of motor oil) have been successfully delivered through a 25G thin wall needle, in less than 7 seconds, using their revolutionary autoinjector.

Oval is a cutting-edge autoinjector company based in Cambridge UK. Their autoinjector technology solves currently unsolvable problems in the industry for drug containment and for the end user.

Oval are highly focussed and agile, and it is therefore not surprising that they are proving to be a global success and are continuously growing their team.

The automatic delivery of high viscosity drugs is an important milestone for injection delivery, as there is currently no-known automatic injection device, with a needle, on the market which can deliver these viscosities.

Viscosity has been a huge problem for many biopharmaceutical formulators as many biologics are very viscous.

There has been no effective way of delivering high viscosity drugs through a prefilled syringe, without extreme pain to the patient (due a large needle bore) and physical discomfort, to the care-giver, when administering the injection (due to high injection forces).

Not only does this mean that these wonder drugs (often coined magic bullets) can be administered through the Oval device, but they can be administered by the patient in the comfort of their own home.

Oval has wide experimental expertise in the design and testing of primary drug containers, for high viscosity drugs, in their specifically designed laboratories.

Testing of pharmaceutical companies’ drugs, to see if they can be delivered in an Oval device, is proving to be a popular service for biopharmaceutical companies.

Oval also has a new technology which should enable much higher viscosities (100,000 cPs) to be administered subcutaneously.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!